FDA Approved Products
6,646 products with lifecycle intelligence, competitive pressure scores, and patent timelines.
CUVPOSA
glycopyrrolate
LOE Approaching
Merz Therapeutics
ORAL · SOLUTION
chronic severe drooling in patients aged 3-16 years with neurologic conditions associated with problem drooling (e
2010
NDA30/100
CYANOCOBALAMIN
cyanocobalamin
LOE Approaching
AbbVie
INJECTION · INJECTABLE
anemia
1949
NDA30/100
CYANOKIT
hydroxocobalamin
LOE Approaching
INJECTION · INJECTABLE
knownsuspected cyanide poisoning
2006
NDA30/100
CYCLAPEN-W
cyclacillin
LOE Approaching
Thayer Medical
ORAL · FOR SUSPENSION
1979
NDA30/100
CYCLAPEN-W
cyclacillin
LOE Approaching
Thayer Medical
ORAL · TABLET
1979
NDA30/100
CYCLESSA
desogestrel; ethinyl estradiol
LOE Approaching
Aspen Surgical
ORAL-28 · TABLET
pregnancy in women
2000
NDA30/100
CYCLOCORT
amcinonide
LOE Approaching
Astellas
TOPICAL · OINTMENT
1981
NDA30/100
CYCLOCORT
amcinonide
LOE Approaching
Astellas
TOPICAL · LOTION
1988
NDA30/100
CYCLOCORT
amcinonide
LOE Approaching
Astellas
TOPICAL · CREAM
1979
NDA30/100
CYCLOPHOSPHAMIDE
cyclophosphamide injection, solution
Growth
Baxter
INTRAVENOUS · SOLUTION
lymphocytic lymphomamixed-cell type lymphoma+5
2023
NDA30/100
CYCLOPHOSPHAMIDE
cyclophosphamide
Growth
Novartis
INTRAVENOUS · SOLUTION
lymphocytic lymphomamixed-cell type lymphoma+9
2023
NDA30/100
CYCLOPHOSPHAMIDE
cyclophosphamide
Peak
Hikma
ORAL · CAPSULE
biopsy proven minimal change nephrotic syndrome in pediatric patientslymphoma+2
2013
NDA30/100
CYKLOKAPRON
tranexamic acid
LOE Approaching
Pfizer
ORAL · TABLET
hemophilia for short-term use (2 to 8 days) to reduceprevent hemorrhage+2
1986
NDA30/100
CYKLOKAPRON
tranexamic acid
LOE Approaching
Pfizer
INJECTION · INJECTABLE
hemophilia for short-term use (2 to 8 days) to reduceprevent hemorrhage+2
1986
NDA30/100
CYLERT
pemoline
LOE Approaching
Abbott
ORAL · TABLET, CHEWABLE
1976
NDA30/100
CYLERT
pemoline
LOE Approaching
Abbott
ORAL · TABLET
1975
NDA30/100
CYMBALTA
duloxetine hydrochloride
LOE Approaching
Eli Lilly and Company
ORAL · CAPSULE, DELAYED REL PELLETS
the following conditions: Major depressive disorder (MDD) in adults () Generalized anxiety disorder (GAD) in adultsolder () Diabetic peripheral neuropathic pain (DPNP) in adults () Fibromyalgia (FM) in adults+2
2004
NDA30/100
CYMBALTA
duloxetine hydrochloride
LOE Approaching
Eli Lilly and Company
ORAL · CAPSULE, DELAYED REL PELLETS
the following conditions: Major depressive disorder (MDD) in adults () Generalized anxiety disorder (GAD) in adultsolder () Diabetic peripheral neuropathic pain (DPNP) in adults () Fibromyalgia (FM) in adults+2
2010
NDA30/100
CYMBALTA
duloxetine hydrochloride
LOE Approaching
Eli Lilly and Company
ORAL · CAPSULE, DELAYED REL PELLETS
the following conditions: Major depressive disorder (MDD) in adults () Generalized anxiety disorder (GAD) in adultsolder () Diabetic peripheral neuropathic pain (DPNP) in adults () Fibromyalgia (FM) in adults+2
2004
NDA30/100
CYMBALTA
duloxetine hydrochloride
LOE Approaching
Eli Lilly and Company
ORAL · CAPSULE, DELAYED REL PELLETS
the following conditions: Major depressive disorder (MDD) in adults () Generalized anxiety disorder (GAD) in adultsolder () Diabetic peripheral neuropathic pain (DPNP) in adults () Fibromyalgia (FM) in adults+2
2008
NDA30/100
CYSTADANE
betaine
LOE Approaching
Recordati
ORAL · FOR SOLUTION
1996
NDA30/100
CYSTADROPS
cysteamine hydrochloride
Peak
Recordati
OPHTHALMIC · SOLUTION/DROPS
corneal cystine crystal deposits in adultschildren with cystinosis
2020
NDA30/100
CYSTAGON
cysteamine bitartrate
LOE Approaching
Viatris (2)
ORAL · CAPSULE
nephropathic cystinosis in children
1994
NDA30/100
CYSTARAN
cysteamine hydrochloride
Peak
Leadiant Biosciences
OPHTHALMIC · SOLUTION/DROPS
corneal cystine crystal accumulation in patients with cystinosis
2012
NDA30/100